Compare iShares MSCI Singapore ETF (EWS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Zoetis Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.9, while Zoetis Inc trades at $77 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EWS | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $32.09 | $156.76 |
52-Week Low | $26.47 | $71.91 |
Market Cap | — | $31.25B |
Enterprise Value | — | $38.54B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZTS trades at $74.08, down 1.74% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results including $9.47B revenue, $2.67B net income, and a 28.03% net margin, but missed Q1 2026 EPS estimates. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU.
Despite near-term legal overhangs and a recent earnings miss, ZTS maintains robust profitability and a consensus price target of $101.43 implies significant upside. Key risks include litigation outcomes and competitive pressures in the companion animal segment, while solid cash flow and high ROE support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
